Borg M, Wen SWC, Nederby L, et al. - Researchers tested the performance of the seven-panel TAA (tumor-related autoantibodies) assay (EarlyCDT Lung), mainly its ability to detect cancer, in a cohort of patients (n = 246) referred from their general practitioner on suspicion of lung cancer. They found an overall sensitivity of 33 % for lung cancer and 31 % for primary lung cancer and lung metastases combined, in the cohort. In age groups, the observed sensitivity was 11 % (60 years or below), 31 % (61−75 years) and 55 % (>75 years). A sensitivity of 33 % and 44 % was revealed in patients with at least 10 tobacco pack years and in those with at least 50 tobacco pack years, respectively. In stage I-II lung cancer patients and in those with stage III-IV, the assay offered a sensitivity of 21 % and 40 %, respectively. Findings revealed that the performance displayed by the EarlyCDT Lung test was the best in elderly, late stage lung cancer patients with a heavy smoking history. In the light of these results, it was inferred that EarlyCDT Lung test lacks sufficient sensitivity to be used as part of inclusion criteria in a low-dose computed tomography program for lung cancer detection.